NuMedii Overview

  • Founded
  • 2008
Founded
  • Status
  • Private
  • Employees
  • 8
Employees
  • Latest Deal Type
  • Series A
  • Latest Deal Amount
  • $1.85M
Latest Deal Amount
  • Investors
  • 6

NuMedii General Information

Description

Developer of new drugs and precision therapies intended to address high unmet medical needs. The company identifies compounds that modulate diverse networks involved in diseases and can help with myriad aspects of drug discovery including identifying patient subgroups, new therapeutic options, and biomarkers, thereby enabling researchers to harness big data and artificial intelligence to rapidly discover connections between drugs and diseases at a systems level.

Contact Information

Website
www.numedii.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 66 Bovet Road
  • Suite 320
  • San Mateo, CA 94402
  • United States
+1 (650) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

NuMedii Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series A) 13-May-2015 $1.85M 00.000 000.00 Completed Generating Revenue
2. Later Stage VC (Series A) 26-Jun-2013 00.00 00.00 00.000 Completed Generating Revenue
1. Accelerator/Incubator 07-Sep-2012 Completed Generating Revenue
To view NuMedii’s complete valuation and funding history, request access »

NuMedii Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 0,000,000 00.000000 00.00 00.0 00.0 00 00.0 00.000
Series A 00,000,000 00.000000 00.00 00.0 00.0 00 00.0 00.000
To view NuMedii’s complete cap table history, request access »

NuMedii Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of new drugs and precision therapies intended to address high unmet medical needs. The company identifies comp
Drug Discovery
San Mateo, CA
8 As of 2020
00.000
00.00 0000-00-00
00000000000 00.000

000000

mco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in volup
0000 000000000
Cambridge, MA
0 As of 0000
00.00
00000000000 00.00

00000000

e cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in cu
0000 000000000
San Francisco, CA
00 As of 0000
00000
0000 0000-00-00
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

NuMedii Competitors (23)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Qrativ Venture Capital-Backed Cambridge, MA 0 00.00 00000000000 00.00
00000000 Venture Capital-Backed San Francisco, CA 00 00000 00000000000 00000
0000000 Venture Capital-Backed Toronto, Canada 00 000.00 00000 000.00
00 000000000000 Venture Capital-Backed Guilford, CT 00 0000 000000000 - 0000
000000000 Formerly VC-backed Milpitas, CA 000 000000&0
You’re viewing 5 of 23 competitors. Get the full list »

NuMedii Executive Team (9)

Name Title Board Seat Contact Info
Tarangini Deshpande Ph.D Co-Founder, Chief Executive Officer & President
Atul Butte MD Co-Founder & Scientific Advisor
Jason Tsai MD Vice President, Translational & Precision Medicine
Samuel Saks MD Chairman of Drug Development, Clinical Advisory Board
You’re viewing 4 of 9 executive team members. Get the full list »

NuMedii Board Members (8)

Name Representing Role Since
Athena Countouriotis MD Self Board Member 000 0000
Kenneth Bahk NuMedii Board Observer 000 0000
Ravi Mhatre Lightspeed Venture Partners Board Observer 000 0000
Samuel Saks MD Self Chairman of Drug Development, Clinical Advisory Board 000 0000
Ted Driscoll Ph.D Claremont Creek Ventures Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

NuMedii Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

NuMedii Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Seraph Group Venture Capital Minority 000 0000 000000 0
TSVC Venture Capital Minority 000 0000 000000 0
Claremont Creek Ventures Hedge Fund Minority 000 0000 000000 0
Life Science Angels Angel Group Minority 000 0000 000000 0
Lightspeed Venture Partners Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »